Navigation Links
Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery
Date:10/13/2011

CAMBRIDGE, Mass., Oct. 13, 2011 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA) technology, today announced results from a clinical evaluation of its Prostate Specific Antigen (PSA) test, a fifth-generation digital immunoassay, demonstrating that the assay is a reliable predictor of five-year biochemical recurrence (BCR)-free survival following radical prostatectomy (RP).  The pilot study was published online by the British Journal of Urology International.  

"These results have important implications for the way prostatectomy patients will be managed in the future," states Dr. Herbert Lepor, prostate cancer expert and Chairman of the Department of Urology at NYU School of Medicine.  "Not only will physicians be able to reassure patients who are at low risk of recurrence following radical prostatectomy, but the identification of a reliable predictor of recurrence soon after surgery has important implications for the frequency of PSA testing and selection of candidates for adjuvant therapy.  In addition to providing patients with peace of mind, implementation of this test could lead to a reduction in healthcare costs."  

To determine the ability of this test to predict five-year BCR-free survival following RP, researchers utilized frozen serum specimens, provided by NYU Langone Medical Center and the Johns Hopkins University School of Medicine, from men who had undergone RP and who had no evidence of BCR using conventional PSA measurement methods.  The Quanterix single molecule PSA assay, which has an analytical sensitivity 1000-fold lower than conventional ultrasensitive PSA assays, was capable of accurately measuring PSA levels in all men following surgery.   Researchers found that the PSA nadir value (lowest level of PSA following RP) was a significant predictor of BCR.  A Kaplan Meir analysis demonstrated that 100% of men with low PSA nadir values did not develop BCR, whereas 63% of men with higher PSA values eventually recurred.  The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the SiMoA PSA test was 100%, 75%, 69% and 100% respectively.  

"We are encouraged by these results, which further supports the value of our SiMoA platform," said Martin Madaus, Ph.D., Executive Chairman of Quanterix.  "We are actively validating assays important in oncology and several other applications while working towards our goal of automating the SiMoA system to offer a menu of assays to the life sciences and in vitro diagnostics markets."

Data from this pilot study was also presented at the American Association of Clinical Chemistry in July and focused on the analytical performance of the PSA test, which demonstrated improved sensitivity over current PSA assays.  

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quanterix Digital ELISA Measures Low Abundance Biomarkers of Inflammation in Crohns Disease
2. Quanterix and STRATEC Announce Strategic Partnership
3. Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability
4. Quanterix Announces New Technology Evaluation Agreement
5. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
6. Pandora Founder Tim Westergren and Co-Discoverer of DNA Dr. James Watson Meet
7. Health fears over CO2 storage are unfounded, study shows
8. Major grant from the National Science Foundation will sustain UCSB materials research through 2017
9. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
10. Society of Interventional Radiology Foundation Funds Howard Hughes Medical Institute Award
11. Society of Interventional Radiology Foundation Welcomes Corporate Gift From Sirtex Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... launched Rosalind™, the first-ever genomics analysis platform specifically designed for life science ... in honor of pioneering researcher Rosalind Franklin, who made a major contribution ...
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply ... a time. So which eye do you rinse first if a dangerous substance enters both ... Duo Eye Wash with its unique dual eye piece. , “Whether its dirt and ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published in ... and fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched ... , After comparing the results from the fresh and frozen transfer cohorts, the ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
Breaking Biology News(10 mins):